Company intelligence / Profile preview

SRW Laboratories

Auckland, New Zealand

Ownership: Private
Development stage: Other

Overview

In a 12-month clinical trial published in Aging Journal, SRW’s Cel1/2/3 products demonstrated reversal of biological age by up to 5.71 years via DNA methylation clocks in healthy US adults

Therapeutic areas: OtherNeurologyPsychiatry
Modalities: Small moleculeNatural productNutraceutical
Industry: Food & Nutrition

Partnerships

Collaborations with leading longevity scientists and advisory board members worldwide; no major pharmaceutical partnerships disclosed

Beyond the preview

Go deeper on SRW Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRW Laboratories.

Explore the full profile